PE20070366A1 - Compuestos derivados de pirazolina sustituidos como moduladores de los receptores de cannabinoides 1 (cb1) - Google Patents

Compuestos derivados de pirazolina sustituidos como moduladores de los receptores de cannabinoides 1 (cb1)

Info

Publication number
PE20070366A1
PE20070366A1 PE2006000849A PE2006000849A PE20070366A1 PE 20070366 A1 PE20070366 A1 PE 20070366A1 PE 2006000849 A PE2006000849 A PE 2006000849A PE 2006000849 A PE2006000849 A PE 2006000849A PE 20070366 A1 PE20070366 A1 PE 20070366A1
Authority
PE
Peru
Prior art keywords
modulators
alkyl
substituted
phenyl
optionally substituted
Prior art date
Application number
PE2006000849A
Other languages
English (en)
Inventor
Maria Rosa Cuberes-Altisen
Original Assignee
Dr Esteve Labor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Esteve Labor filed Critical Dr Esteve Labor
Publication of PE20070366A1 publication Critical patent/PE20070366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 ES FENILO OPCIONALMENTE SUSTITUIDO CON ALQUILO(C1-C6), ALCOXILO(C1-C6), HALOGENO, ENTRE OTROS; R2 ES FENILO OPCIONALMENTE SUSTITUIDO CON ALQUILO(C1-C6), CF3, CN, OH, ENTRE OTROS; R3 ES UN CICLOALIFATICO (C3-C8) SATURADO O INSATURADO OPCIONALMENTE SUSTITUIDO CON ALQUILO(C1-C6), ARILO O HETEROARILO DE 5 O 6 MIEMBROS OPCIONALMENTE SUSTITUIDO CON ALQUILO(C1-C6), ENTRE OTROS. ES UN COMPUESTO PREFERIDO: (S)-N-PIPERIDINIL-5-(4-CLORO-FENIL)-1-(2,4-DICLOROFENIL)-4,5-DIDHIDRO-1H-PIRAZOL-3-CARBOXAMIDA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARCION. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES DE CANNABINOIDES 1 (CB1) SIENDO UTILES EN EL TRATAMIENTO DE BULIMIA, OBESIDAD, PSICOSIS, ESQUIZOFRENIA, EPILEPSIA, ENFERMEDAD DE PARKINSON, OSTEOPOROSIS
PE2006000849A 2005-07-15 2006-07-14 Compuestos derivados de pirazolina sustituidos como moduladores de los receptores de cannabinoides 1 (cb1) PE20070366A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05384008A EP1743892A1 (en) 2005-07-15 2005-07-15 Substituted pyrazoline compounds, their preparation and use as medicaments
US70548205P 2005-08-05 2005-08-05

Publications (1)

Publication Number Publication Date
PE20070366A1 true PE20070366A1 (es) 2007-05-30

Family

ID=35337642

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000849A PE20070366A1 (es) 2005-07-15 2006-07-14 Compuestos derivados de pirazolina sustituidos como moduladores de los receptores de cannabinoides 1 (cb1)

Country Status (5)

Country Link
US (1) US7968582B2 (es)
EP (2) EP1743892A1 (es)
PE (1) PE20070366A1 (es)
TW (1) TW200745042A (es)
WO (1) WO2007009686A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745476B2 (en) * 2004-01-30 2010-06-29 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (en) 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1944295A1 (en) * 2007-01-15 2008-07-16 Laboratorios del Dr. Esteve S.A. Non-racemic mixtures of (R)-N-piperidinyl-5-(4-chlorophenyl)1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide and (S)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide
EP1950202A1 (en) * 2007-01-24 2008-07-30 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments with ACAT inhibition activity
TW200948798A (en) * 2008-04-23 2009-12-01 Solvay Pharm Bv (5R)-1, 5-diaryl-4, 5-dihydro-1H-pyrazole-3-carboxamidine derivatives having CB1-antagonistic activity
EP2151234A1 (en) * 2008-07-28 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
EP2314578A1 (en) 2009-10-13 2011-04-27 Esteve Química, S.A. Cinchonidine salt of (4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid, useful as intermediate in the preparation of cannabinoid CB1 neutral antagonists

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1053661B (it) 1966-09-27 1981-10-10 Farmacosmici S P A Ammidi dell acido 3 5 metil 5 3 pirazol carbossilico
DE3540934A1 (de) 1985-11-19 1987-05-27 Bayer Ag Verwendung von pyrazolidindionen, neue pyrazolidindione und deren verwendung
US5091405A (en) * 1987-01-05 1992-02-25 E. I. Du Pont De Nemours And Company Insecticidal pyrazolines
DE3765782D1 (de) 1987-01-05 1990-11-29 Du Pont Pyrazolin mit insektizidischer aktivitaet.
FR2613720B1 (fr) 1987-04-10 1990-01-19 Esteve Labor Dr Derives d'aryl-heteroaryl carbinols avec activite analgesique
JPH02117605A (ja) * 1988-10-26 1990-05-02 Nippon Nohyaku Co Ltd 白蟻防除剤及びその使用方法
EP0543930A1 (en) 1990-08-17 1993-06-02 E.I. Du Pont De Nemours And Company Arthropodicidal pyrazolines, pyrazolidines and hydrazines
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2742147B1 (fr) 1995-12-06 1998-02-27 Esteve Labor Dr Procede de separation de carbinols
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
ES2130079B1 (es) 1997-07-10 2000-01-16 Esteve Labor Dr Resolucion de aminas
ES2130083B1 (es) 1997-08-04 2000-01-16 Esteve Labor Dr Procedimiento para la obtencion de los enantiomeros de cizolirtina.
ES2150353B1 (es) 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
ES2137138B1 (es) * 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
EP1177188B1 (en) 1999-05-12 2005-10-12 Ortho-McNeil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
AU771668C (en) 1999-06-16 2005-08-11 Temple University - Of The Commonwealth System Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
ATE346047T1 (de) 2000-03-23 2006-12-15 Solvay Pharm Bv 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer aktivität
DE60125541T2 (de) 2000-06-22 2007-10-11 Pharmos Corp. Neue nicht psychotropische cannabinoide
US6956033B2 (en) 2000-08-01 2005-10-18 Ono Pharmaceutical Co., Ltd. 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient
ES2174757B1 (es) * 2001-04-06 2003-11-01 Esteve Labor Dr Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
ES2180449B1 (es) 2001-07-06 2004-01-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
PL368441A1 (en) 2001-09-21 2005-03-21 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
US6509367B1 (en) 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
TW200302726A (en) 2002-01-31 2003-08-16 Ono Pharmaceutical Co Nitrogen-containing bicyclic compound and medicament containing same as active ingredient
US20050137251A1 (en) 2002-03-18 2005-06-23 Aaron Garzon Dexanabinol and dexanabinol analogs regulate inflammation related genes
FR2839718B1 (fr) 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
EP1606019A1 (en) 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
KR101204247B1 (ko) 2003-07-22 2012-11-22 아스텍스 테라퓨틱스 리미티드 3,4-이치환된 1ｈ-피라졸 화합물 및 그의 시클린 의존성키나제 (ｃｄｋ) 및 글리코겐 합성효소 키나제-3(ｇｓｋ-3) 조정제로서 용도
ES2311972T3 (es) * 2004-01-30 2009-02-16 Solvay Pharmaceuticals B.V. Derivados 1,3,5-trisubstituidos de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1.
US7745476B2 (en) 2004-01-30 2010-06-29 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
ES2238923B1 (es) 2004-02-16 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Nuevos derivados pirazolinicos sustituidos.
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
ES2329915T3 (es) * 2004-02-20 2009-12-02 Astrazeneca Ab Derivados de 1,5-difenilpirazol 3-sustituidos utiles como moduladores de cb1.
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
JP4232703B2 (ja) 2004-07-13 2009-03-04 ヤマハ株式会社 ディジタルミキサ装置
US20060106014A1 (en) 2004-10-14 2006-05-18 Sekhar Boddupalli Methods for treating diabetes
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
JP2008528469A (ja) 2005-01-21 2008-07-31 アステックス・セラピューティクス・リミテッド ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤
JP5475235B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
AR053662A1 (es) 2005-01-21 2007-05-16 Astex Therapeutics Ltd Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
US7897589B2 (en) * 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (en) 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
EP1757587A1 (en) * 2005-07-15 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
US7763607B2 (en) * 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators

Also Published As

Publication number Publication date
EP1910332A2 (en) 2008-04-16
TW200745042A (en) 2007-12-16
EP1743892A1 (en) 2007-01-17
WO2007009686A2 (en) 2007-01-25
US20070015811A1 (en) 2007-01-18
US7968582B2 (en) 2011-06-28
WO2007009686A3 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
PE20070366A1 (es) Compuestos derivados de pirazolina sustituidos como moduladores de los receptores de cannabinoides 1 (cb1)
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide
GB0517191D0 (en) Compounds
PE20070370A1 (es) Compuestos derivados de carboxamidas como agentes fungicidas
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
PE20070720A1 (es) Derivados de fenilo como antagonistas del receptor 3 de la histamina
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
HK1146053A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
HK1146056A1 (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
GB0507601D0 (en) Compounds
PE20070194A1 (es) Compuestos de pirazolina 4-sustituidos como moduladores de cb1
PE20080984A1 (es) Aminometil-2-imidazoles
HK1146054A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
GEP20146099B (en) Fused imidazole carboxamides as trpv3 modulators
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
ATE486058T1 (de) Prolinamidderivate als nk3-antagonisten
MX2007010572A (es) Compuestos de cinolina y su uso como moduladores de receptor x de higado.
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
PE20091270A1 (es) Derivados de azetidinas con actividad sobre receptores cb1 y su preparacion
DE602007012531D1 (de) Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
TW200612924A (en) Oxazolidinones containing oxindoles as antibacterial agents
DE602007012683D1 (de) Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente

Legal Events

Date Code Title Description
FA Abandonment or withdrawal